Hyperlactatemia is one of the important metabolic abnormalities in HIV infected patients. The prevalence of hyperlactatemia in natural course of HIV disease is approximately about 2%. Aim of this study is to estimate the prevalence of hyperlactatemia in HIV patients receiving two antiretroviral regimens, advocated by NACO by monitoring the plasma lactate levels. This study was taken up with 200 patients to compare the prevalence of hyperlactatemia of two commonly used NACO regimens (zidovudine+ lamivudine+ nevirapine) Vs (stavudine+ lamivudine+ nevirapine). The plasma lactate levels were estimated between 9 th to 18 th month after initiation of antiretroviral therapy. The comparision and correlation between plasma lactate levels, CD4 counts and haemoglobin percentage in both regimens was done. There was statistically significant rise in the plasma lactate levels (p<0.05) in both regimens. The increase in plasma lactate levels is more in stavudine group compared to zidovudine group. There was low degree of positive correlation between plasma lactate and haemoglobin in Stavudine group but negative correlation between Plasma lactate and CD4 counts in both groups. More focus is needed on Pharmacovigilance of NRTIs induced hyperlactatemia especially Stavudine.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.